Skip to main content

Table 2 Characteristics of extrauterine prevention alone for newborns born to HBsAg- and/or HBeAg-positive women

From: Immunization interventions to interrupt hepatitis B virus mother-to-child transmission: a meta-analysis of randomized controlled trials

Reference E 1) Infant’s Immune prophylaxis 2)(schedule/month ) Sample size (n) Newborn 7-12month infant >12 month child
HBsAg-pos HBsAb-pos HBsAg-pos HBsAb-pos HBsAg-pos HBsAb-pos
Lo 1985 [59]-[61] 1 T: HBIG50 IU(0) + PDV5ug T:36 NR NR T:4 T:32 NR NR
(0.5,1.5,2.5); C: PDV5ug (0.5,1.5,2.5) C:38 C: 9 C:30
Sha 1985 [62] 1 T: HBIG 0.5 ml(0) + PDV 20ug (0,1,2,12); T:19 T:13 T:18 T:4 T :10 NR NR
C: PDV 20 ug(0,1,2,12) C:10 C:7 C:0 C:1 C:5
Wu 1986 [63] 1 T : HBIG 1 ml(0) + PDV 20ug (1,2,3) T:13; T:1; NR NR NR NR NR
C : PDV 20 ug(1,2,3) C:6 C:0
Farmer 1987 [64] 1 T: HBIG 0.25 ml (25 IU/kg)(0,1.5), T:21 NR NR T:3 T:17 NR NR
PDV5 ug(0,1.5, 6) C: PDV5 ug (0,1.5,6) C:18 C:4 C:13
Theppisai 1987 [65] 1 T: HBIG 200 IU(0) + PDV 10 ug (0,1,6) T:27 NR NR T:2 NR NR NR
C: PDV 10 ug(0,1,6) C:18 C:2
Ip1 989 [8],[66],[67] 1 T: PDV3 ug(0,1,2,6) + HBIG(0) T:64 NR NR T:8 NR T:9 T:47
C: PDV3 ug(0,1,2,6) C:64 C:15 C:15 C:52
Assateerawatt 1993 [68] 1 T:HBIG100IU(0) + RV20 ug (0,1,2,12) T:30 NR NR T:1 T:25 T:1 T:24
C: RV20 ug(0,1,2,12) C:30 C:2 C:22 C:3 C:21
Li 1994 [69] 1 T : HBIG 200 IU(0) + PDV (0,1,6) T1:20; C1:22 T1:7; C1: 7; T1:18;C1:3 T1:1; C1:3 T1:16; C1:19 NR NR
C : PDV (1,2,3). T2:20; C2:21 T2:7; C2: 8; T2:9; C2:2 T2:7; C2:7 T2:17; C2:11
PDV including 10 ug, 20 ug and 30 ug T3:22; C3:21 T3:7; C3: 7 T3:9; C3:2 T3:1; C3:2 T3:20; C3:20
Zhao 1994 [70] 1 T : HBIG 60 IU(0) + V 10 ug (0,1,6) T:40 T:2 T:35 T:2 T:36 NR NR
C : V 10 ug(0,1,6) C:26 C:5 C:9 C:7 C:15
Kang 1995 [71] 1 T: HBIG 200 IU(0,1) + RV1 10 ug (0,1,6) T:44 NR NR NR NR T: 0 T: 43
C: RV1 20 ug(0,1,6) C:41 C: 5 C: 35
Poovorawan 1997 [72]-[74] 1 T: HBIG 100 IU(0) + RV 10 ug (0,1,6,60) T:64 T:1 NR T: 0 T: 58 T:1 T:39
C: RV 10 ug(0,1,6,60) C:63 C:3 C:3 C: 54 C:3 C:35
Lin 2000 [75] 1 T : HBIG 50 IU(0) + RV 10 ug (0,1,6) T:31 T:4 T: 26 NR NR NR NR
C : RV 10 ug(0,1,6) C:39 C:2 C: 36
Meng 2001 [76] 1 T : HBIG 50 IU(0) + RV 10 ug (0,1,6) T:50 NR NR NR NR T:4 T:45
C : RV 10 ug(0,1,6) C:52 C:7 C:43
Wang 2000-2001 [77],[78] 1 T: HBIG 100 IU(0,1) + RV 20 ug (1,2,7) T:104; C:241 T:20; C :76 NR T:21; C:81 NR T:26; C:96 NR
2 C: PDV 20 ug(0,1,6) T:157; C:122 T:19; C:25 NR T:22; C:26 NR T:28;C:35 NR
Sehgal 1992 [79],[80] 13) T: HBIG0.5 ml(0) + PDV10 ug(0,1,2) T:7; C:7 NR NR T:1; C:1 T:5;C:4 NR NR
2 C: PDV10 ug(0,1,2) T:17:C:14 NR NR T:1; C:1 T:13;C:13 NR NR
Xu 1995 [12] 1 T: HBIG 250 IU(0) + PDV 20 ug(0,1,6) T:11; C:31 NR NR T:1; C:10 NR T:1; C:10 NR
2 C: PDV 20 ug(0,1,6) T:17; C:29 NR NR T:0; C:2 NR T:1; C:2 NR
  1. 1)E = HBeAg, 1 refers to pregnancy with HBeAg and HBsAg positivity; 2refers to pregnancy with HBsAg positivity and HBeAg negativity. 2) Vaccination schedule is filled in () by the unit of month.
  2. T, experimental group; C, control group.
  3. V, vaccine; PDV, plasma-derived vaccine; RV, recombinant vaccine; HBIG, hepatitis B immunoglobulin; NR, not reported. 3)Six newborns infected with HBV at birth were excluded owing to the absence of intervention.
\